ArticleDiscover oncology2026
Construction and validation of nomogram for the cancer-specific death in children and adolescents‑onset lymphoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphomas in children and adolescents accounted for about 25% of all lymphoma cases. The cancer-specific death (CSD) of children and adolescent-onset remains dismal and varies widely in different individuals. The current investigation aimed to develop a predicting nomogram to evaluate CSD risk in children and adolescents‑onset lymphoma with data from the Surveillance, Epidemiology and End Results (SEER) database.
methodsThe pathological variables of lymphomas patients were extracted from the SEER database. A competing risk model was used to identify independent factors for CSD. The predicting nomogram was also developed. The performance of the nomogram was evaluated with calibration curves, receiver operating characteristic curve and decision curve.
resultsA total of 7349 lymphoma cases were selected in our investigation, which were separated into the training (n = 5144) and testing (n = 2205) cohorts. The results of univariate and multivariate analysis demonstrated age, race, year of diagnosis, pathological subtype, tumor grade, tumor stage, and chemotherapy as independent risk factors for CSD in lymphoma cases. The 1-year, 3-year-, and 5-year AUCs of ROC curves of nomogram for CSD in lymphoma were 0.855, 0.827, and 0.810 in the training cohort and 0.862, 0.829, and 0.812 in the testing cohort, respectively. Further analysis suggested a good agreement between the observed outcome and the predicted probabilities in the calibration curves in training cohort and testing cohort. Moreover, decision curve analysis also indicted good clinical utility of the nomogram models in training cohort and validation cohort.
conclusionThe nomogram shows good accuracy and reliability in evaluating the risk of CSD in children and adolescents‑onset lymphoma, and it could provide some theoretical support for clinicians to make decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.